Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?
The small molecule macrocyclic lactone ivermectin, approved by the US Food and Drug Administration for parasitic infections, has received renewed attention in the last eight years due to its apparent exciting potential as an antiviral. It was identified in a high-throughput chemical screen as inhibi...
Main Authors: | David A. Jans, Kylie M. Wagstaff |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/9/9/2100 |
Similar Items
-
Antiviral Activity of Ivermectin Against SARS-CoV-2: An Old-Fashioned Dog with a New Trick—A Literature Review
by: Mudatsir Mudatsir, et al.
Published: (2020-08-01) -
Role of ivermectin in COVID-19: Wishful thinking or scientific optimism
by: Prafull Mohan, et al.
Published: (2020-01-01) -
COVID-19: Ivermectin; Molecular Mechanisms, Limitations, Suggestions
by: Mustafa KESMEN, et al.
Published: (2020-12-01) -
Identification of Broad-Spectrum Antiviral Compounds by Targeting Viral Entry
by: Michela Mazzon, et al.
Published: (2019-02-01) -
Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens
by: Georgi Momekov, et al.
Published: (2020-01-01)